GGHC
ENZY

Gilder Gagnon Howe & Co’s Enzymotec Ltd ENZY Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-216,512
Closed -$4.77M – 330
2014
Q1 		$4.77M Sell
216,512
-1,720
-0.8% -$45.6K 0.07% 163
2013
Q4 		$5.89M Buy
+218,232
New +$5.19M 0.08% 139

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MCM
Matterhorn Capital Management San Antonio, Texas $151M AUM 14.71% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
MACM
March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gilder Gagnon Howe & Co's ENZY Position: Q2 2014 in Review

Gilder Gagnon Howe & Co sold out of Enzymotec Ltd (ENZY) in Q2 2014, closing a stake of 216,512 shares — an estimated $4.77M sold.

Gilder Gagnon Howe & Co first reported a position in ENZY in Q4 2013 and held it in 2 quarters. The position peaked at $5.89M in Q4 2013. 25 funds tracked by Wall St. Rank hold ENZY as of Q2 2014.

  • Gilder Gagnon Howe & Co reported no remaining Enzymotec Ltd position as of Q2 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 216,512 Enzymotec Ltd shares in Q2 2014, an estimated $4.77M.
  • Gilder Gagnon Howe & Co first reported a position in Enzymotec Ltd in Q4 2013 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Enzymotec Ltd position peaked at $5.89M in Q4 2013.
  • 25 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q2 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2014, filed 1 Aug 2014.